EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Bivalent chromatin: a developmental balancing act tipped in cancer

Eleanor Glancy, Natalie Choy, Melanie A Eckersley-Maslin iD

Biochemical Society Transactions · 28.02.2024 · 52 (1) · 217-229

DOI: 10.1042/bst20230426 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical Society Transactions, online erschienen am 22.02.2024. Verfasst von Eleanor Glancy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia. Hauptthemen laut MEDLINE: Chromatin, Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bivalent chromatin is defined by the co-occurrence of otherwise opposing H3K4me3 and H3K27me3 modifications and is typically located at unmethylated promoters of lowly transcribed genes. In embryonic stem cells, bivalent chromatin has been proposed to poise developmental genes for future activation, silencing or stable repression upon lineage commitment. Normally, bivalent chromatin is kept in tight balance in cells, in part through the activity of the MLL/COMPASS-like and Polycomb repressive complexes that deposit the H3K4me3 and H3K27me3 modifications, respectively, but also emerging novel regulators including DPPA2/4, QSER1, BEND3, TET1 and METTL14. In cancers, both the deregulation of existing domains and the creation of de novo bivalent states is associated with either the activation or silencing of transcriptional programmes. This may facilitate diverse aspects of cancer pathology including epithelial-to-mesenchymal plasticity, chemoresistance and immune evasion. Here, we review current methods for detecting bivalent chromatin and discuss the factors involved in the formation and fine-tuning of bivalent domains. Finally, we examine how the deregulation of chromatin bivalency in the context of cancer could facilitate and/or reflect cancer cell adaptation. We propose a model in which bivalent chromatin represents a dynamic balance between otherwise opposing states, where the underlying DNA sequence is primed for the future activation or repression. Shifting this balance in any direction disrupts the tight equilibrium and tips cells into an altered epigenetic and phenotypic space, facilitating both developmental and cancer processes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChromatinNeoplasmsHumansHistonesEmbryonic Stem CellsBase SequenceMixed Function OxygenasesProto-Oncogene Proteins

Stichwörter der Autor:innen

bivalencybivalent chromatinepigeneticsgene expression and regulationhistone methylationmethylation

Substanzen

ChromatinHistonesTET1 protein, humanMixed Function OxygenasesProto-Oncogene Proteins

Autor:innen und Institutionen

  • Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.
  • Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria 3010, Australia.
  • Department of Anatomy and Physiology, The University of Melbourne, Melbourne, Victoria 3010, Australia.

ORCID-Profile: Melanie A Eckersley-Maslin

Zitieren

APA

Glancy, E., Choy, N., & Eckersley-Maslin, M. A. (2024). Bivalent chromatin: a developmental balancing act tipped in cancer. Biochemical Society Transactions, 52(1), 217-229. https://doi.org/10.1042/bst20230426

Vancouver

Glancy E, Choy N, Eckersley-Maslin MA. Bivalent chromatin: a developmental balancing act tipped in cancer. Biochemical Society Transactions. 2024;52(1):217-229. doi:10.1042/bst20230426

BibTeX
@article{Glancy2024,
  author = {Glancy, Eleanor and Choy, Natalie and Eckersley-Maslin, Melanie A},
  title = {Bivalent chromatin: a developmental balancing act tipped in cancer},
  journal = {Biochemical Society Transactions},
  year = {2024},
  volume = {52},
  number = {1},
  pages = {217--229},
  doi = {10.1042/bst20230426}
}
Kostenlos starten →